Wedbush Forecasts Pharvaris’ FY2025 Earnings (NASDAQ:PHVS)

Pharvaris N.V. (NASDAQ:PHVS) – Wedbush raised their FY2025 earnings per share estimates for Pharvaris in a report issued on Wednesday, November 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($3.41) per share for the year, up from their previous forecast of ($3.49). Wedbush currently has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($1.88) EPS and FY2028 earnings at $0.58 EPS.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08.

PHVS has been the topic of a number of other reports. Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. JMP Securities decreased their price objective on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.57.

Pharvaris Stock Down 3.8%

Shares of PHVS stock opened at $23.97 on Monday. The firm has a market cap of $1.25 billion, a P/E ratio of -7.47 and a beta of -2.78. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33. The business has a 50-day moving average price of $23.26 and a two-hundred day moving average price of $20.78.

Institutional Investors Weigh In On Pharvaris

Several institutional investors have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Pharvaris during the second quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris during the third quarter valued at $75,000. Public Employees Retirement System of Ohio lifted its holdings in Pharvaris by 39.3% in the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock valued at $156,000 after acquiring an additional 1,769 shares during the period. Finally, Legal & General Group Plc boosted its position in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.